Data from Pharmawand - Curated by Toby Galbraith - Date added 17 May 2017

Ampio Pharmaceuticals, Inc. announces initiation of a single injection study to meet the “unmet medical need” of treating the severe pain and loss of function associated with Kellgren-Lawrence (KL) grade 4 osteoarthritis of the knee (OAK) with a primary endpoint that follows the Osteoarthritis Research Society International (OARSI) guidance, utilizing the Outcome Measures in Rheumatology Clincal Trials (OMERACT) OMERACT-OARSI responder rate.

Dr. David Bar-Or, Ampio’s Chief Science Officer, clarified “In compliance with FDA guidance, this trial will be smaller than our prior trials with 171 patients, randomization of 6 to 1 (Ampion/Saline) on patients with severe OAK, defined radiologically as KL 4 patients. The 6-1 randomization will preserve blinding and prevent the bias in the assessment that might be associated with an unblinded evaluation; however, only Ampion treated patients will be evaluated. This 12-week study will evaluate the responder rate of Ampion treated patients as defined by OARSI, which includes pain, function, and patient global assessment (PGA). The outcome of this study will contribute to the label of Ampion which may include pain, function, and patient global assessment. Using the OMERACT-OARSI responder rate definition and the analysis proposed in this protocol, all previous Ampion single injections clinical trials would have successfully met this endpoint.”


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.


Essential screening, diagnosis and best strategies to manage bedwetting.

+ 3 more

Visit Bedwetting

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

Visit Cushing's Syndrome

Related Content